Psychedelic Business Spotlight: November 5
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.